Brussels, Belgium-based UCB entered into a global licensing deal with Roche and Genentech to develop and commercialize UCB0107 in Alzheimer’s disease.

AC Immune initiated the second highest dosing group in the company’s Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease, based on encouraging interim data from the initial dosing cohort.

The U.S. Food and Drug Administration approved drugmaker Eli Lilly and Co.’s radioactive compound to detect tau, an important characteristic of Alzheimer’s disease.

Carlsbad, California-based Ionis Pharmaceuticals licensed the company’s IONIS-MAPTRX antisense therapy to leading biotech firm Biogen Inc.

Researchers at Washington University School of Medicine in St. Louis found further evidence that microglia are the key link between the accumulation of abnormal proteins, including beta-amyloid and tau, in the brain and the actual brain damage observed in Alzheimer’s patients.

As pharma companies struggle with developing a treatment for Alzheimer’s disease, researchers continue to find evidence that links the dreaded form of dementia to other medical and health issues. The latest news suggests a potential link between Alzheimer’s and menopause.

Researchers with the University of California, Los Angeles (UCLA) Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice.

Researchers at the University of Texas Health Science Center at San Antonio found a type of cellular stress in Alzheimer’s disease for the first time that is involved in cancer and aging.

Biogen Inc. reported far better-than-expected second-quarter 2018 profit, driven by strong demand of the company’s Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast.

Disrupting deep sleep boosts the amount of an Alzheimer’s disease-related protein called amyloid-beta in the fluid bathing the brain and spinal cord, new research suggests.